Healthcare insights
The latest insights for healthcare professionals to help you make the most of your practice and personal goals.
Healthcare and pharma insights
Insights
Healthcare and pharma insights
Read our latest healthcare and pharma insights.
Pharma and life sciences insights
Read our latest pharma and life sciences insights.
Sign up to hear more from us
Select your interests and receive our latest insights, event invitations, news and more.
12 February 2025
A survivor’s guide to the changing market
In the past few weeks, the US president has kept financial markets and business leaders on their toes. With a surge of incoming information, analysts and investment managers know that systemic risks are rising, but how best can they navigate these changes?
Are UK businesses prepared for AI?
We’ve measured the AI preparedness of over 300 businesses in the UK. Find out the results.
4 February 2025
How trade wars could impact portfolios & business
This past week was predictably eventful, and the upcoming week promises to be even more so. The US President continued his reshaping of both the American and global economy, imposing 25% tariffs on Mexico and Canada and an additional 10% on China beginning on 1 February, promising that Europe is next.
24 January 2025
Quarterly Investment Outlook – Q1 2025
Looking ahead in 2025, there are obvious challenges to the global trade environment, whilst above-target inflation and the resulting elevated interest rates add further grit to the wheels of the global economy at a time when equity valuations are looking a little expensive. At the same time, acute recessionary and inflationary risks have diminished, meaning we remain essentially neutral in terms of...
22 January 2025
Economic challenges facing the new US President
Donald Trump officially became President of the United States of America for the second time. In the last few days, we have heard a lot about the new President’s plans: a precipitous hike in tariffs, deregulation in the bank, tech, energy and pharma sectors, reducing corporate taxes, a “cultural revolution”, ending global strife, rewriting global borders, ending illegal immigration… and so much more.
6 December 2024
What the Budget means for the life sciences sector
As we step into 2025, the effects of the Autumn Budget 2024 will start to take shape, leaving businesses in the pharma and life sciences sector grappling with its implications. Was it a step forward or a setback? Only time will tell as the changes take effect.
13 November 2024
How has the Autumn Budget impacted doctors?
Labour's first budget brought some positive news in terms of its proposed investment in the NHS. However, with it seeking to balance the books there were some significant changes which will impact doctors’ businesses, particularly in relation to General Practice.
11 November 2024
Boehringer Ingelheim's £21 million VAT victory
In a significant decision for the pharmaceutical industry, the UK First Tier Tribunal (FTT) has ruled in favour of Boehringer Ingelheim, allowing the company to reclaim £21 million of overpaid VAT. This ruling is a major development for suppliers of branded medicines to the NHS, offering clarity on how VAT should be treated in relation to rebate payments under the UK’s voluntary price control schemes.
25 October 2024
Is the R&D tax credit regime fit for purpose?
Recent developments suggest that the R&D tax credit regime, established almost 25 years ago to support innovative UK businesses, is facing critical challenges. Although it has played a crucial role in driving value creation in sectors like pharmaceuticals and life sciences, its effectiveness is increasingly questioned.
4 October 2024
How we are supporting NHS pension members
Our specialist medical accounting team has partnered with Dr Tony Goldstone to support NHS pension members affected by the McCloud ruling and the impact on pension annual allowance tax.
21 August 2024
Third party risk management
In the last few weeks, we have seen both the ransomware attack on the NHS in the news, and more recently, the impact caused by a software bug in an update from a cyber security firm, causing IT outages across the globe. These two incidents, added to the traditional high risks of issues such as bribery and corruption, stress the importance of third party risk management and due diligence.
Pharma and Life Sciences - Exploring tax reliefs
Pharma and life sciences businesses, understandably, tend to focus on the science and development of ideas and the groundbreaking therapies this might lead to. However, leveraging all available resources, such as allowances and tax reliefs, is also something these companies should be considering. While leading pharmaceutical companies have large departments dedicated to this, smaller businesses in...
Private equity and deals activity in the sector
05/10/2023. Tarifa Simpson, our Healthcare & Life Sciences Co-Lead and Due Diligence Partner, gives her views on the current deals environment within the healthcare and life sciences sector.
Bringing the ‘E’ and the ’S’ together
Acting on the principles embodied in ESG (environmental, social and governance) is fraught with difficulty.
Collaborative arrangements and tax
Why companies within the Pharmaceutical and Life Sciences sector need to be aware of the tax implications before entering into collaborative arrangements.